Xeris Biopharma Holdings Inc. (XERS)
NASDAQ: XERSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
XERS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.84B
- Forward P/E
- 27.32
- EPS (TTM)
- -$0.10
- Dividend yield
- None
- 52-week range
- 5.25 – 11.33
- Day range
- 9.91 – 10.27
- Volume / Avg
- 2.22M / 2.19M
- Beta
- —
- Shares outstanding
- 182.32M
- Next earnings
- Nov 5, 2026
52-week range
XERS stock today
On Oct 7, XERS ended the session at $10.11, adding $0.04 (0.40%), versus the S&P 500's 0.22% decline. At this level, XERS sits in the middle of its 52-week range of $5.25 to $11.33: 10.8% below the high, set on Sep 29, 2026 and 92.6% above the low. XERS is up 28.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 22.1%.
Xeris Biopharma has posted a net loss over the last twelve months (EPS of -$0.10), so its P/E ratio is not meaningful. Xeris Biopharma's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Xeris Biopharma
Company profileXeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. John P. Shannon
- Headquarters
- Chicago, IL
- Employees
- 435
- IPO year
- 2018
- Website
- xerispharma.com
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$12.86+27.20%
- Strong buy 1
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $0.02
Xeris Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZBIOZenas BioPharma Inc. | 28.18 | +4.60% | $1.84B | vs XERS |
| SRPTSarepta Therapeutics Inc. | 17.50 | +1.10% | $1.85B | vs XERS |
| ADRXADARx Pharmaceuticals Inc. | 17.33 | -6.73% | $1.85B | vs XERS |
| XNCRXencor Inc. | 24.26 | -0.41% | $1.80B | vs XERS |
| TRVITrevi Therapeutics Inc. | 13.14 | -0.30% | $1.87B | vs XERS |
| BHVNBiohaven Ltd. | 11.88 | -1.66% | $1.79B | vs XERS |
| PVLAPalvella Therapeutics Inc. | 130.59 | +2.02% | $1.88B | vs XERS |
| AGIOAgios Pharmaceuticals Inc. | 31.79 | +0.22% | $1.90B | vs XERS |
Indexes, lists and sector
Xeris Biopharma stock FAQ
What is Xeris Biopharma's stock price today?
XERS last traded at $10.11 as of Oct 7, 4:00 PM EDT, up 0.40% on the day. Prices are delayed at least 15 minutes.
When is Xeris Biopharma's next earnings date?
Xeris Biopharma is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $0.02.
Who is Xeris Biopharma's CEO?
Mr. John P. Shannon is the chief executive officer of Xeris Biopharma Holdings Inc., which has about 435 employees.
What is the XERS 52-week high?
The 52-week high for XERS is $11.33 and the 52-week low is $5.25. The stock is currently 10.8% below its high.